Economic burden and treatment patterns among patients with mantle cell lymphoma in the United States: a retrospective study of administrative claims data

Although a range of treatments are used to manage MCL, including targeted therapies such as ibrutinib, there is a high HRU and cost burden driven by disease-related medical costs that increase with subsequent LOTs.